At a glance
- Originator Servier
- Class Vasoconstrictors
- Mechanism of Action Serotonin 2A receptor antagonists; Thromboxane A2 receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Thrombosis
Most Recent Events
- 03 Nov 2003 No development reported - Preclinical for Thrombosis in France (unspecified route)
- 18 Sep 2001 New profile
- 18 Sep 2001 Preclinical development for Thrombosis in France (Unknown route)